Evidence map›Paper›PMID 34208786›Full record

ArticleInternational journal of molecular sciences2021

Long-Chain Acylcarnitines Decrease the Phosphorylation of the Insulin Receptor at Tyr1151 Through a PTP1B-Dependent Mechanism.

Karlis Vilks, Melita Videja, Marina Makrecka-Kuka, Martins Katkevics, Eduards Sevostjanovs, Aiga Grandane, Maija Dambrova, Edgars Liepinsh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Plasma Metabolomics and Breast Cancer Risk over 20 Years of Follow-up among Postmenopausal Women in the Nurses' Health Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Karlis VilksLaboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles Str. 21, LV-1006 Riga, Latvia.ORCID 0000-0002-4203-2129
Melita VidejaLaboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles Str. 21, LV-1006 Riga, Latvia.ORCID 0000-0002-3453-0099
Marina Makrecka-KukaLaboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles Str. 21, LV-1006 Riga, Latvia.ORCID 0000-0003-4549-1993
Martins KatkevicsBiologically Active Compound Synthesis Laboratory, Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia.ORCID 0000-0003-1547-0075
Eduards SevostjanovsLaboratory of Physical Organic Chemistry, Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia.
Aiga GrandaneOrganic Synthesis Group, Latvian Institute of Organic Synthesis, LV-1006 Riga, Latvia.ORCID 0000-0002-9563-131X
Maija DambrovaLaboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles Str. 21, LV-1006 Riga, Latvia.ORCID 0000-0002-1739-0928
Edgars LiepinshLaboratory of Pharmaceutical Pharmacology, Latvian Institute of Organic Synthesis, Aizkraukles Str. 21, LV-1006 Riga, Latvia.ORCID 0000-0003-2213-8337
Latvijas Organiskās Sintēzes Institūts · LV

Funding

Latvian Institute of Organic Synthesis, student grant IG-2017-03Latvijas Zinātnes Padome LZP-2018/1-0082
6 · The paper itself

Abstract

The accumulation of lipid intermediates may interfere with energy metabolism pathways and regulate cellular energy supplies. As increased levels of long-chain acylcarnitines have been linked to insulin resistance, we investigated the effects of long-chain acylcarnitines on key components of the insulin signalling pathway. We discovered that palmitoylcarnitine induces dephosphorylation of the insulin receptor (InsR) through increased activity of protein tyrosine phosphatase 1B (PTP1B). Palmitoylcarnitine suppresses protein kinase B (Akt) phosphorylation at Ser473, and this effect is not alleviated by the inhibition of PTP1B by the insulin sensitizer bis-(maltolato)-oxovanadium (IV). This result indicates that palmitoylcarnitine affects Akt activity independently of the InsR phosphorylation level. Inhibition of protein kinase C and protein phosphatase 2A does not affect the palmitoylcarnitine-mediated inhibition of Akt Ser473 phosphorylation. Additionally, palmitoylcarnitine markedly stimulates insulin release by suppressing Akt Ser473 phosphorylation in insulin-secreting RIN5F cells. In conclusion, long-chain acylcarnitines activate PTP1B and decrease InsR Tyr1151 phosphorylation and Akt Ser473 phosphorylation, thus limiting the cellular response to insulin stimulation.

Indexed as

AnimalsCarnitineCHO CellsCricetulusCyclic AMP-Dependent Protein KinasesInsulinInsulin ResistanceModels, BiologicalPhosphorylationProtein Phosphatase 2Protein Tyrosine Phosphatase, Non-Receptor Type 1Proto-Oncogene Proteins c-aktReceptor, InsulinTyrosineacylcarnitineCarnitineCyclic AMP-Dependent Protein KinasesInsulinProtein Phosphatase 2Protein Tyrosine Phosphatase, Non-Receptor Type 1Proto-Oncogene Proteins c-aktPTPN1 protein, humanReceptor, InsulinTyrosineAktinsulin receptorinsulin resistancelong-chain acylcarnitinespalmitoylcarnitineprotein tyrosine phosphatase 1B

Identifiers

PMID34208786
PMCPMC8235348
OpenAlexW3166506136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.